Animal/human reassortant rotaviruses show promise as an effective vaccine against rotavirus-induced acute gastroenteritis.
Does not support changes to current rotavirus prevention; leaves open reassortant vaccine feasibility pending rigorous trials.
Rotaviruses are the predominate aetiological agent of acute gastroenteritis in humans and are responsible for almost a million infant deaths each year. Major technical challenges to the development of an effective live rotavirus vaccine include lack of any clear-cut serological correlate for protection, selection of proper serotypes to provide broad protection and formulation and delivery by the oral route. Nevertheless, recent work suggests that animal/human reassortant rotaviruses offer the prospect of an effective vaccine.
No takes yet. Share an insight, caveat, or question.
Shaw et al. (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: